Literature DB >> 15667646

Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?

Claartje Gosselaar1, Monique J Roobol, Fritz H Schröder.   

Abstract

Screening for prostate cancer at low prostate-specific antigen (PSA) levels (<or=4.0 ng/mL) risks detecting clinically insignificant cancers, which are of no threat to the man. In this review we evaluate the prevalence and tumour characteristics of prostate cancer detected at low PSA levels, comparing screening studies, cystoprostatectomy series and autopsy data. The favourable characteristics of tumours detectable at very low PSA levels seem to justify the conclusion that an unknown but sizeable proportion of the cancers found at biopsy are clinically insignificant.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15667646     DOI: 10.1111/j.1464-410X.2005.05324.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  15 in total

1.  [PSA 2010--the beginning of a new era in early detection of prostate cancer].

Authors:  C Börgermann; M Sieverding; P Fornara; M Graefen; P Hammerer; A Semjonow; F Schröder; H Rübben
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

Review 2.  Is it time to consider a role for MRI before prostate biopsy?

Authors:  Hashim U Ahmed; Alex Kirkham; Manit Arya; Rowland Illing; Alex Freeman; Clare Allen; Mark Emberton
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675

3.  Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.

Authors:  Scott A Tomlins; Sheila M J Aubin; Javed Siddiqui; Robert J Lonigro; Laurie Sefton-Miller; Siobhan Miick; Sarah Williamsen; Petrea Hodge; Jessica Meinke; Amy Blase; Yvonne Penabella; John R Day; Radhika Varambally; Bo Han; David Wood; Lei Wang; Martin G Sanda; Mark A Rubin; Daniel R Rhodes; Brent Hollenbeck; Kyoko Sakamoto; Jonathan L Silberstein; Yves Fradet; James B Amberson; Stephanie Meyers; Nallasivam Palanisamy; Harry Rittenhouse; John T Wei; Jack Groskopf; Arul M Chinnaiyan
Journal:  Sci Transl Med       Date:  2011-08-03       Impact factor: 17.956

4.  [Problems, objective, and substance of early detection of prostate cancer].

Authors:  C Börgermann; H Loertzer; P Hammerer; P Fornara; M Graefen; H Rübben
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

Review 5.  Epithelial cancers in the post-genomic era: should we reconsider our lifestyle?

Authors:  Jeff M P Holly; Li Zeng; Claire M Perks
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

6.  Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance.

Authors:  Jeri Kim; James Ebertowski; Matthew Janiga; Jorge Arzola; Gayle Gillespie; Michael Fountain; Douglas Soderdahl; Edith Canby-Hagino; Sally Elsamanoudi; Jennifer Gurski; John W Davis; Patricia A Parker; Douglas D Boyd
Journal:  BJU Int       Date:  2013-01-25       Impact factor: 5.588

7.  Joint spatial survival modeling for the age at diagnosis and the vital outcome of prostate cancer.

Authors:  Huafeng Zhou; Andrew B Lawson; James R Hebert; Elizabeth H Slate; Elizabeth G Hill
Journal:  Stat Med       Date:  2008-08-15       Impact factor: 2.373

Review 8.  [PSA--Quo vadis?].

Authors:  C Börgermann; H Loertzer; H-J Luboldt; P Hammerer; P Fornara; M Graefen; H Rübben
Journal:  Urologe A       Date:  2009-09       Impact factor: 0.639

9.  High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy.

Authors:  Martin Mørck Mortensen; Søren Høyer; Torben Falck Orntoft; Karina Dalsgaard Sørensen; Lars Dyrskjøt; Michael Borre
Journal:  BMC Cancer       Date:  2014-11-21       Impact factor: 4.430

Review 10.  Overdiagnosis and overtreatment of early detected prostate cancer.

Authors:  C H Bangma; S Roemeling; F H Schröder
Journal:  World J Urol       Date:  2007-02-14       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.